These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 30168968)

  • 1. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VI. Standard Treatment for Multiple Myeloma].
    Ito S; Takano M
    Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1238-45. PubMed ID: 30168968
    [No Abstract]   [Full Text] [Related]  

  • 2. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VII. Hematopoietic Stem Cell Transplantation for Multiple Myeloma].
    Nakaseko C
    Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1246-54. PubMed ID: 30168969
    [No Abstract]   [Full Text] [Related]  

  • 3. What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
    Giralt S; Stadtmauer E; McCarthy P
    Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S30-2. PubMed ID: 21195307
    [No Abstract]   [Full Text] [Related]  

  • 4. [Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma].
    García Laraña J; Díaz Mediavilla J; Martínez R; Lahuerta JJ; Alegre A; Odriozola J; Sureda A; San Miguel J; De la Rubia J; Escudero A; Conde E; Bladé J; Cabrera R; Gastearena J; Besalduch J; Vidal MJ; Hernández F; Rifon J; Leon A; Mataix R; Parody R; Moraleda JM; Solano C; de Pablos JM; Sánchez JJ
    Sangre (Barc); 1997 Apr; 42 Suppl 1():38-41. PubMed ID: 9381300
    [No Abstract]   [Full Text] [Related]  

  • 5. [Standard therapy for multiple myeloma].
    Tokuhira M; Kizaki M
    Rinsho Ketsueki; 2012 Oct; 53(10):1675-88. PubMed ID: 23037740
    [No Abstract]   [Full Text] [Related]  

  • 6. New strategies in transplantation therapy.
    Harousseau JL
    Oncology (Williston Park); 2004 Nov; 18(13):1614-5, 1617. PubMed ID: 15648294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal timing for transplant in multiple myeloma.
    Rajkumar SV
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):684-6. PubMed ID: 22402513
    [No Abstract]   [Full Text] [Related]  

  • 8. [Physiopathology, diagnosis and therapy in multiple myeloma (discussion)].
    Nihon Naika Gakkai Zasshi; 1995 Jul; 84(7):1132-49. PubMed ID: 7561372
    [No Abstract]   [Full Text] [Related]  

  • 9. Response evaluation and monitoring of multiple myeloma.
    Fernández de Larrea C; Delforge M; Davies F; Bladé J
    Expert Rev Hematol; 2014 Feb; 7(1):33-42. PubMed ID: 24483347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VIII. Novel Drugs for Multiple Myeloma].
    Shibayama H
    Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1255-60. PubMed ID: 30168970
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.
    Montefusco V; Spina F; Patriarca F; Offidani M; Bruno B; Montanari M; Mussetti A; Sperotto A; Scortechini I; Dodero A; Fanin R; Valagussa P; Corradini P
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):424-8. PubMed ID: 23142330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 13. Stem cell transplant for first relapse from the multiple myeloma research foundation.
    Anderson KC; Vesole DH
    Oncology (Williston Park); 2006 Dec; 20(14):1818, 1820-1, 1825-6. PubMed ID: 17263130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney Transplantation for Kidney Failure Due to Multiple Myeloma: Case Reports.
    Le TX; Wolf JL; Peralta CA; Webber AB
    Am J Kidney Dis; 2017 Jun; 69(6):858-862. PubMed ID: 28320553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolution and impact of therapy in multiple myeloma.
    Laubach JP; Richardson PG; Anderson KC
    Med Oncol; 2010 Jun; 27 Suppl 1():S1-6. PubMed ID: 20169425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
    Sinha S; Lacy M; Mikhael J; Hayman S; Buadi F; Detweiler-Short K; Dispenzieri A; Gertz M; Dingli D; Rajkumar SV; Kumar SK
    Leukemia; 2012 Apr; 26(4):839-41. PubMed ID: 21986842
    [No Abstract]   [Full Text] [Related]  

  • 17. VI. Autologous stem cell transplantation and maintenance therapy.
    Moreau P
    Hematol Oncol; 2013 Jun; 31 Suppl 1():42-6. PubMed ID: 23775648
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
    Tacchetti P; Pezzi A; Zamagni E; Pantani L; Rocchi S; Zannetti BA; Mancuso K; Rizzello I; Cavo M
    Haematologica; 2017 Mar; 102(3):e104-e107. PubMed ID: 27909220
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
    Kuroda J
    Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
    Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
    Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.